



**Application Number:** 1IK2BX003308-01A1

**FAIN:** IK2BX003308

**Principal Investigator(s):**

Dhakshin Ramanathan, BS

**Project Title:** Enhancing Neural Circuit Plasticity to Promote Recovery After TBI

Yu, Rebecca  
VA Grants Manager  
4150 Clement Street  
San Francisco, CA 941211545

We are pleased to inform you that funding in the amount of \$285,125 (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) is being considered to support the above named project at San Francisco VA Health Care System.

This is not an indication, however, of the final award. For some ORD Research & Development Services, the budget in Section I reflects the recommendations of the review panel and other administrative changes; for other R&D Services, the budget reflects what was requested in the application.

Budget negotiations may occur as part of the JIT process. Because we may not yet have a fiscal year budget and all just-in-time (JIT) issues have not been resolved, project start dates are uncertain. We will attempt to maintain continuity for ongoing programs, but negotiation of start dates will not begin until all required JIT documentation has been approved. Please note that, as always, funding is dependent upon the availability of funds.

A final Notice of Award will be issued after all JIT issues have been resolved and all budget negotiations are completed. Refusal of this award must be communicated to the appropriate representative of the ORD Research & Development Service named above.

Each publication, press release or other document that cites results from VA-supported research must include an acknowledgment of VA support and disclaimer (e.g., "The project described was supported by Award Number I01BX007080 from the Biomedical Laboratory Research & Development Service of the VA Office of Research and Development").

If you have any questions about this award, please contact the individual(s) referenced in Section II below.

Additional information follows

---

**SECTION I – PROPOSED AWARD DATA – 1K2BX003308-01A1****Award Calculation (U.S. Dollars)**

<b>Salaries and Wages</b>	\$190,125
<b>Personnel Costs (Subtotal)</b>	\$190,125
<b>Equipment</b>	\$30,000
<b>Travel Costs</b>	\$1,000
<b>Other Costs</b>	\$64,000
<b>TOTAL PROPOSED AWARD AMOUNT</b>	<b>\$285,125</b>

<b>SUMMARY OF PROPOSED TOTALS FOR ALL YEARS</b>	
<b>YR</b>	<b>THIS AWARD</b>
1	\$285,125
2	\$260,830
3	\$266,704
4	\$272,756
5	\$278,989

Recommended future year total cost support is subject to the availability of funds and satisfactory progress of the project

---

**SECTION II – CONTACT INFORMATION – 1K2BX003308-01A1**

The Scientific Review Officer (SRO) named below is responsible for the determination of the proposed budget shown in Section I above. This budget may reflect recommendations of the reviewers, as well as administrative changes needed to meet the requirements of the awarding ORD Research and Development Service. Initial inquiries about the proposed budget should be directed to:

**SRO:** Amanda E. Hunt  
**Email:** amanda.hunt@va.gov **Phone:** 202-443-5684

---

**SECTION III – TERMS AND CONDITIONS – 1K2BX003308-01A1**

This award is based on the above titled application submitted to and approved by VA-ORD, and is subject to the terms and conditions incorporated either directly or by reference in the following:

- a. All awards are dependent upon the availability of funds.
- b. Funding is contingent upon the review and approval of JIT compliance documentation and resolution of any administrative issues. Remember that all information provided must be current and that documentation, including proposal title and principal investigator name, must correspond exactly to the work described in the application. Please complete JIT documentation as soon as possible.
- c. Award recipients are responsible to ensure that VA is properly acknowledged on all public reports and presentations. Failure to acknowledge VA affiliation and support may result in termination of the award. For additional information, please refer to [http://www1.va.gov/vhapublications/ViewPublication.asp?pub\\_ID=361](http://www1.va.gov/vhapublications/ViewPublication.asp?pub_ID=361).
- d. This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

This award has been assigned the Federal Award Identification Number (FAIN) 1K2BX003308. Recipients must document the assigned FAIN on each consortium/subaward issued under this award.

---

**SECTION IV – BX Special Terms and Conditions – 1K2BX003308-01A1**

Personnel Costs (Subtotal) in Section I above include Salary and Fringe Benefits for the PI and all other individuals named in the budget section of the application. If not listed separately, Fringe benefits are included in Salaries and Wages.

This award is subject to all budgetary constraints/limits described in the VA SF-424 Application Guide and the specific RFA to which this application was submitted.

All funded interventional clinical trials must be registered in ClinicalTrials.gov before funds can be released, and certification must be received from the Facility Director that appropriate resources will be provided for oversight.

Award recipients are responsible for reporting inventions derived in the performance of work under this project. For additional information, please refer to [http://www.va.gov/vhapublications/ViewPublication.asp?pub\\_ID=403](http://www.va.gov/vhapublications/ViewPublication.asp?pub_ID=403).

<b>Grant Number:</b>	25437
<b>Grantee (P.I.):</b>	Dhakshin Ramanathan, M.D., Ph.D.
<b>Institution:</b>	University of California, San Diego
<b>Installment Amount:</b>	\$17,500.00 (1 of 4)
<b>Total Grant Amount:</b>	\$70,000.00
<b><u>Original</u> Project Period:</b>	January 15, 2017 – January 14, 2019
<b>Project Title:</b>	Using Closed-loop Stimulation Technologies to Modulate Oscillatory Deficits in a Rodent Model of Schizophrenia

### I. General

- This grant is for a period up to 24 months and is contingent upon the provision of the requirements defined below.
- The Brain & Behavior Research Foundation (“Foundation”) must be notified in writing of all awards/grants awarded to Grantee (P.I.) subsequent to the NARSAD Grant throughout the duration of the grant.
- A grantee has up to six months from the originally scheduled start date to establish a revised start date.
- If the grant start date is delayed, the grant period will be changed to reflect this, and will result in a late payment schedule.
- The NARSAD Grant is intended for the original grant recipient and may not be assumed by another investigator.
- Any project changes to the NARSAD Grant must be submitted to the Foundation in writing for review and pre-approval.
- Second year funding will be made pending the availability of funds.
- Funding after the grant period is non-renewable, but a no-cost extension (NCE) can be requested for 6 or 12 months.

### II. Use of Funds

- Expenditures must be made in accordance with the grantee’s institutional policy and must be used to support the research budget described in the NARSAD Grant application. Budget revisions greater than \$7,500 for equipment and \$1,000 for salary or travel categories must be submitted to the Foundation in writing for pre-approval.
- Funds provided under this grant cannot be used for political purposes or in attempts to influence governmental bodies other than by making available the results of the research or the fact of the grant.
- **Indirect costs** are *not* allowed for the **NARSAD Young Investigator Grant**.
- Unexpended funds from the first year may carry over to the second year.
- All funds remaining at the end of the project or extension must be returned to the Foundation, in U.S. dollars.

### III. Financial Records

- The grantee’s institution is responsible for the expenditure of the grant, and for maintaining supporting records of receipts and expenditures. It is the responsibility of the grantee to request that a final (cumulative) financial report be submitted to the Foundation. A cumulative financial report is required within ninety (90) days after termination of the grant, together with the refund of any unexpended balance. This report should reflect total grant amount, expenditures and any balance (due to the Foundation), in U.S. dollars.

#### **IV. Human Subjects, Animals, and Recombinant DNA**

- Research supported by Foundation funds that involves humans as research subjects, animals, or experiments involving recombinant DNA techniques, must comply with the current guidelines of the Department of Health and Human Services concerning such matters. By accepting the NARSAD Grant, the institution agrees to accept responsibility for such compliance. Institutional Review Board (IRB/Ethics Committee) approval and/or Institutional Animal Care and Use Committee (IACUC) approval is required prior to the start of the grant. If no approval is necessary, the investigator must submit a statement to this effect in writing. It is the responsibility of the grantee to provide appropriate renewals to the Foundation. No funds will be released until proof of IRB/IACUC approval is received.

#### **V. Patents/Intellectual Property**

- If an invention results wholly or in part from the Foundation support, the Foundation shall be notified promptly in writing. While the title to any such invention will normally be vested in the grantee institution, it is expected the inventor(s), the institution, and the Foundation will reach a mutually satisfactory agreement concerning disposition of royalties, license fees, or other income.

#### **VI. Acknowledgment of Support**

- All grantees must acknowledge the Foundation sponsored work in written materials and speeches, such as articles, announcements, presentations, and media interviews, as well as in related public venues dealing with scientific research.
- Any publications resulting from research supported by the NARSAD Grant shall acknowledge Foundation support, such as, “Supported by a NARSAD Young Investigator Grant from the Brain & Behavior Research Foundation.” A reprint of each such publication shall be sent to the Foundation at [grants@bbrfoundation.org](mailto:grants@bbrfoundation.org).

#### **VII. Change of Institution**

- Institutional transfer requests shall be directed to the Foundation for approval by the Scientific Council. The request shall include: a letter from the investigator requesting the transfer; a letter from the institution originally awarded the grant indicating agreement to relinquish the grant, a financial report with the amount of funds to be transferred (if funds were disbursed); a letter from the new institution indicating acceptance of the grant; a letter from a mentor in the grantee's new department stating willingness to act in this capacity and asserting that the project can continue; new contact and payment information; new institution's IRB/IACUC approval (if not required, please submit a short statement to that effect) and any budget revisions.

#### **VIII. Early Termination**

- Should the grantee leave the institution to which the grant was awarded, and not wish to transfer the grant to another eligible institution, the grant shall be terminated. Termination is effective the date the grantee's association with the project ends. A final progress report and a final financial report must be submitted within sixty (60) days of the effective date of termination. All unexpended funds must be returned to the Foundation and all future payments will be cancelled.

**IX. Reports/Publications**

**Interim Progress Report**

- An interim one page narrative progress report (and any relevant publications) must be submitted after six months of the project start date. A second progress report must be submitted a year after the submission of the first progress report due date. Subsequent payments are contingent upon receipt and approval of progress reports. No-cost extension recipients (one year or greater) must continue to submit yearly reports on the same schedule.

**Publications**

- See Item VI (Acknowledgment of Support).

**Final Progress Report**

- A final progress report must be submitted within ninety (90) days of grant termination. The final progress report includes a narrative with a statement of relevant findings, subsequent awards/grants received, impact of the NARSAD Grant on the grantee’s career, and copies of relevant publications.

**X. Grant Payments**

- Payments will be made to the investigator’s institution in four (4) equal installments. Payments are contingent upon receipt of required approvals, documentation and progress reports, as noted above.

**XI. Promotional Rights**

- The Foundation reserves the right to utilize information resulting from the NARSAD Grant for promotional efforts, unless the Grantee (P.I.) requests otherwise (due to pending publication), in writing.
- All grantees are asked to submit a web-ready photo and short biography for inclusion on the Foundation website.

**XII. Miscellaneous**

- The Foundation offers certain specialized donor programs, such as the Research Partners Program, which may result in a grantee being selected to participate, in which case he/she may be required to take on a limited number of additional responsibilities, such as a letter acknowledging the individual donor.

**ACCEPTED:**

\_\_\_\_\_  
Signature of Grantee (P.I.)/Date (MM/DD/YYYY)

\_\_\_\_\_  
Institution Official Signature/Date (MM/DD/YYYY)

\_\_\_\_\_  
Institution Employer Identification Number (EIN)

\_\_\_\_\_  
Name of Institution

**BURROUGHS WELLCOME FUND  
AGREEMENT AND STATEMENT OF CONDITIONS  
FOR CAREER AWARDS FOR MEDICAL SCIENTISTS**

INSTITUTION: University of California-San Diego  
GRANT: Career Awards for Medical Scientists  
INVESTIGATOR: Dhakshin Ramanathan, M.D., Ph.D.  
REQUESTID #: 1015644.01 (Must be used in all correspondence with BWF)  
ACTIVATION DATE: June 1, 2017  
PURPOSE:

*This program is intended to foster the development of physician scientists who are early in their careers and to help them make the critical transition to becoming independent investigators.*

---

The Career Award for Medical Scientists is subject to this Agreement and Statement of Conditions. The Career Award for Medical Scientists is made as a grant by the Burroughs Wellcome Fund to the University of California-San Diego on behalf of the named investigator. Acceptance of this grant shows that the sponsoring institution and named investigator agree to the terms and conditions in this document and that the sponsoring institution agrees to oversee administration of the grant in accordance with this document.

---

**GENERAL TERMS AND CONDITIONS:**

1. The award begins June 1, 2017, and ends August 31, 2022. Normally, the postdoctoral and the faculty portions of the award constitute separate grants. Because the named investigator has been offered a faculty position and approved by BWF at the time the award was granted, in this case the entire award amount (\$700,000) will be one grant, paid out over a minimum of five years (see below).

Payment Schedule	Salary and Research	Institutional Allowance	Total
June 15, 2017	\$63,000	\$7,000	\$70,000
September 15, 2017	\$63,000	\$7,000	\$70,000
March 15, 2018	\$63,000	\$7,000	\$70,000
September 14, 2018	\$63,000	\$7,000	\$70,000
March 15, 2019	\$63,000	\$7,000	\$70,000
September 13, 2019	\$63,000	\$7,000	\$70,000
March 13, 2020	\$63,000	\$7,000	\$70,000
September 15, 2020	\$63,000	\$7,000	\$70,000
March 15, 2021	\$63,000	\$7,000	\$70,000
September 15, 2021	\$63,000	\$7,000	\$70,000

*This payment schedule may be interrupted if the carry-over amount (reported on the annual financial report) is greater than a single installment. The Fund reserves the right to temporarily hold further payments until the named investigator or institution notifies the Fund that additional money is needed. Payments will automatically resume if the account balance or carryover amount is below a single installment.*

2. Payments will normally be sent in two equal installments during each year of the Award on March 15 and September 15 unless another agreement is reached with the Fund. The Fund reserves the right to adjust the payment schedule and end date for the grant. The initial installment will be mailed on September 15, 2016, upon receipt of the acceptance of this grant.
3. Burroughs Wellcome Fund requires the institution offering a faculty appointment to make a commitment to the career development of the named investigator in the form of a tenure track faculty appointment. Tenure track appointments are expected to be accompanied by financial support for starting a laboratory and/or salary support. If non-tenure track, the institution must make a significant commitment to the named investigator in the form of financial support for a starting laboratory and/or by providing salary support. Salary support may take the form of a salary supplement or a salary extension beyond the term of the award. Teaching, administrative and clinical activities must not exceed 25% of the awardee's time. Burroughs Wellcome Fund reserves the right to terminate a grant if this commitment is judged to be inadequate.
4. The grant will be subject to annual review based on the named investigator's performance as evidenced by the named investigator's annual progress reports and other information that Burroughs Wellcome Fund may request. The Fund reserves the right to discontinue this grant upon determination that the named investigator or his/her institution is not adhering to the terms set forth in this Agreement or adequate progress is not demonstrated. In such cases, if a grant is discontinued, the named investigator shall receive a 30-day written notice. Any funds unspent at the time the notice is issued shall be returned to the Fund.

#### USE OF FUNDS AND REPORTING:

5. By policy, Burroughs Wellcome Fund does not permit indirect costs to be charged against its grants.
6. The institutional allowance is to support the cost of fringe benefits, such as health insurance premiums, vacation, or retirement, so the named investigator will not experience a reduction in salary to compensate for benefits that are not provided by the institution. The fee is secondarily intended to defray institutional costs associated with the administration of the grant. When the cost of fringe benefits exceeds the institutional allowance, the institution is expected to cover these costs as an indication of support for the named investigator. Any portion of the administrative fee, which is not used to support the named investigator's benefits or administrative costs, will be added to the named investigator's research allowance.
7. Of the "salary and research" portion of the grant, up to \$150,000 of BWF award funds may be used toward the awardee's salary in the faculty years. BWF does not require a minimum amount of the award to be used to cover the awardee's salary. If an institution's salary scale for the faculty position exceeds the amounts provided by the grant, then the institution must supplement the named investigator's salary.

8. The research allowance may be used for consumable supplies, equipment, personnel, and travel to scientific meetings as designated by the named investigator. The use of research expenses is at the full discretion of the named investigator and any equipment or supplies purchased through this grant may be transferred to a new institution if the named investigator moves to a new institution. Prior approval by the Fund is required when a single purchase of equipment exceeds \$20,000, when travel exceeds \$8,000 within any one fiscal year, or when research goals and objectives change substantially. The named investigator is responsible for contacting the BWF staff to clarify prior approval requirements.

9. The BWF expects the named investigator to devote no less than 75% of his/her time to research in general.

10. The Burroughs Wellcome Fund is committed to the career development of early career scientists who are supported by BWF funds, including postdoctoral fellows and graduate students. Postdoctoral fellows or graduate students supported by BWF funds should be given substantial support, both in salary, benefits, and appropriate career development attention and guidance from the named investigator on this grant. To do this, a mentoring and career plan should be in place for each postdoctoral fellow and graduate student who is partially or fully supported by this grant. BWF encourages the use of the Individual Development Plan for Postdoctoral Fellows created by the Federation of American Societies for Experimental Biology (FASEB) (<http://opa.faseb.org/pdf/idp.pdf>).

For grants to institutions within the United States, postdoctoral support should meet or exceed the National Institutes of Health (NIH) National Research Service Award scale appropriate for the trainee's level. The current NIH scale is listed below. The named investigator is responsible for ascertaining if changes are made in this scale during the duration of the grant and adjusting the salaries of personnel accordingly (<http://grants1.nih.gov/training/nrsa.htm>).

The current NIH National Research Service Award Scale is:

Predoctoral	\$23,376
<u>Years as Postdoc</u>	<u>Stipend</u>
0	\$43,692
1	\$45,444
2	\$47,268
3	\$49,152
4	\$51,120
5	\$53,160
6	\$55,296
7 or more	\$57,504

Where postdoctoral fellows or graduate students are supported by this grant, the annual progress report must include an affidavit that a training plan for supported trainees and their professional development is in place during the reported year and should indicate the level of support provided.

11. The Burroughs Wellcome Fund is committed to nondiscriminatory practices. If postdoctoral fellows, graduate or undergraduate students are supported by this grant, it is expected that the named investigator will follow the employment practices of his/her institution with regard to non-discrimination.

12. The named investigator may receive outside research funding. Burroughs Wellcome Fund should be informed of stipends or salary supplements from other sources. If BWF funds are not needed to support or supplement the named investigator’s salary, these funds should be added to the research allowance of the named investigator.

13. Burroughs Wellcome Fund’s fiscal year begins on September 1 and ends on August 31. An annual progress report will be required from the named investigator on November 1 of each year. In addition, an annual expenditure report will be required from the financial officer of the sponsoring institution on November 1 of each year. See Table below. The expenditure report must be submitted on the report form provided by the Fund. Based on the November 1<sup>st</sup> deadline, the progress and expenditure reports will cover the following time periods.

Progress and Financial Reports	Progress Reporting Period	Financial Reporting Period	Due Date
1	September 1, 2016 – August 31, 2017	June 1, 2017 – August 31, 2017	November 1, 2017
2	September 1, 2017 – August 31, 2018	September 1, 2017 – August 31, 2018	November 1, 2018
3	September 1, 2018 – August 31, 2019	September 1, 2018 – August 31, 2019	November 1, 2019
4	September 1, 2019 – August 31, 2020	September 1, 2019 – August 31, 2020	November 1, 2020
5	September 1, 2020 – August 31, 2021	September 1, 2020 – August 31, 2021	November 1, 2021
6	September 1, 2021 – August 31, 2022	September 1, 2021 – August 31, 2022	November 1, 2022
No-cost extension	September 1, 2022 – August 31, 2023 <i>(if applicable)</i>	September 1, 2022 – August 31, 2023 <i>(if applicable)</i>	November 1, 2023
No-cost extension	September 1, 2023 – August 31, 2024 <i>(if applicable)</i>	September 1, 2023 – August 31, 2024 <i>(if applicable)</i>	November 1, 2024

Please include the BWF Request ID number on all correspondence. Unexpended funds remaining at the end of each year may be carried forward to the following year. However, if the carry-over amount is greater than a single installment (see item 2), the Fund reserves the right to temporarily interrupt further payments until the named investigator or institution notifies the Fund that additional money is needed. At the conclusion of the grant, the annual progress report and expenditure report shall be submitted as final reports covering the full grant period. Format guidelines for annual and final reports will be provided two months prior to the due dates each year and will be available on our website ([www.bwfund.org](http://www.bwfund.org)).

The progress and financial reports should be sent to the Burroughs Wellcome Fund. **Continued funding for the following year is dependent on the timely receipt and a satisfactory review of these reports by the Fund and its scientific Advisory Committee. Failure to submit progress reports by the due date may result in a termination of the grant.** BWF considers “satisfactory” to mean good faith adherence to the terms of the award and the statement of work outlined in the proposal, and not the Fund’s agreement with the views, findings, opinions, or results of the work covered under this grant. When results are inconsistent with the original hypothesis described in the proposal, the named investigator is expected to develop an alternate approach and justify how the direction of the project will be changed. Continuation of the award

is therefore dependent on the named investigator's productivity and evidence of scholarship, and not on obtaining a particular result. **If, in the estimation of the scientific advisory committee, the named investigator is not adequately progressing, the grant may be terminated.**

14. The grantee institution is responsible for the expenditure of the funds hereby granted and for maintaining adequate supporting records of receipts and expenditures. Such records shall be consistent with generally accepted accounting principles.

15. At the termination of the grant period, grant balances of \$500 or greater must be returned to the Burroughs Wellcome Fund. Grant balances less than \$500 may be retained by the institution. The named investigator may request a no-cost extension at the completion of the grant period. A request for an extension must be made in writing and must include a detailed explanation of the purposes for which the extension is requested. The request for a no-cost extension must be approved and copied to the appropriate representative of the named investigator's institution. In general, no-cost extensions will be granted until the awardee gets tenure. The Fund reserves the right to deny such a request in whole or in part. If the request is approved, it will be incumbent upon the named investigator and his/her institution to provide annual progress and expenditure reports during the no-cost extension period, as well as final progress and expenditure reports at the end of the no-cost extension period. Progress and expenditure reports are due by November 1 of each year during a no-cost extension.

16. This grant is made to the institution on behalf of the named investigator; however, **the named investigator may request to transfer the grant to another institution upon written approval by the Fund.** A request for transfer must be made in writing well in advance of the transfer date and must include an explanation by the named investigator of the reason(s) for which a transfer is requested.

17. Recipients of the BWF Career Award for Medical Scientists are expected to attend BWF sponsored grant recipient meetings and participate in surveys and outcome evaluations. Please note that contact from BWF staff or contractors who are conducting outcome evaluations of BWF grant programs may continue for a number of years after the grant has terminated.

18. In the interest of transparency and public accountability regarding foundation-supported research, BWF shares information about its awardees in a variety of venues, including its website, annual report, and other publications. BWF also deposits data about its awardees in publicly-accessible databases. This data includes information about the grant (project title, dollar amount, lay abstract, whether IRB approval is required, award type, award length), as well as data about the investigator (name, training background, degrees, institution). Demographic data (gender and ethnicity) is shared but under the condition that it only be reported in aggregate. Acceptance of this grant gives BWF permission to include award information (name, degrees, institution, training background, project title, award amount, lay abstract) in its awardee directory and in other publicly accessible databases of privately funded grant awards.

19. Grantees may not hold more than one BWF named award concurrently.

#### PATENTS AND PUBLICATIONS:

20. The named investigator shall follow his/her institution's patent, copyright, and licensure policies for discoveries resulting from research carried out under this grant and for which a patent, copyrights, or licenses are sought.

21. The named investigator shall share research supported by this grant through recognized means, e.g., publications and/or presentations of results in scientific forums.
22. The named investigator is permitted to collaborate with industry, provided that sharing of BWF-funded data through recognized means is not prevented or delayed inappropriately.
23. Burroughs Wellcome Fund will not retain any rights to published results of the funded research. However, all publications resulting from the work sponsored by this BWF grant are to carry the following acknowledgment: "Dhakshin Ramanathan, M.D., Ph.D., holds a Career Award for Medical Scientists from the Burroughs Wellcome Fund." Copies of reprints of any such publications are to be sent to the Fund's office in Research Triangle Park, North Carolina as part of the annual progress report.

FEDERAL, STATE, AND LOCAL COMPLIANCE ISSUES:

24. If any aspect of the research supported by this grant involves the use of human subjects, approval of his/her institution's review board/committee on human research must be obtained prior to grant expenditure. Such research must also comply with appropriate federal, state, and local regulations pertaining to the use of human subjects in research.
25. If animals are to be used in research, the animal facilities and the care of the animals shall conform to the regulations of appropriate federal, state, and local regulations pertaining to the use of animals in research.
26. The named investigator and the institution understand and agree that all institutional policies and local, state, and federal regulations governing the conduct of research will be followed without exception, including, but not limited to, the policies and regulations governing radioactive substances, recombinant DNA, toxic materials, conflict of interest, conflict of commitment, codes of ethics, and specific environmental regulations as appropriate.
27. The sponsoring institution overseeing the administration of this grant is responsible for policy issues of research conduct regarding the named investigator. The BWF expects that the appropriate institutional representative will contact the Fund immediately if a question arises about the named investigator regarding conduct of research or if a change in the institutional policy related to research conduct significantly impacts the ability of the named investigator to conduct research at the sponsoring institution.
28. The Burroughs Wellcome Fund does not assume responsibility for activities supported by the grant and shall not be liable for any activities conducted by the grantee upon receipt of the grant funds.

PUBLICITY:

29. A joint news release by the institution and the Fund announcing the Career Award for Medical Scientists is preferred. Any institutional announcement of this grant should be sent to the Fund's office for approval prior to release.

All reports and communications required for the administration of this grant shall be sent to the following individuals:

*General Terms of the Grant:*

Rolly L. Simpson, Jr.  
Senior Program Officer  
Burroughs Wellcome Fund  
21 TW Alexander Drive  
PO Box 13901  
Research Triangle Park, NC 27709  
Email: [rsimpson@bwfund.org](mailto:rsimpson@bwfund.org)

*Administrative Questions/Progress and  
Financial Reports:*

Debra J. Holmes  
Senior Program Associate  
Phone: (919) 991-5134  
Fax: (919) 991-5194  
Email: [dholmes@bwfund.org](mailto:dholmes@bwfund.org)

*Publicity:* Russ Campbell  
Communications Officer  
Phone: (919) 991-5119  
Fax: (919) 991-5179  
Email: [rcampbell@bwfund.org](mailto:rcampbell@bwfund.org)

Burroughs Wellcome Fund is an independent private foundation, subject to the rules and regulations of the Tax Reform Acts and Internal Revenue Code. Acceptance of the Career Award for Medical Scientists confirms eligibility of the institution to receive contributions under the specified laws and regulations. We ask, therefore, that you confirm acceptance of this grant by signing and returning this agreement by 05/22/2017.

ACCEPTED AND AGREED TO:

---

Printed Name of Institutional Administrative Officer

---

Title of Institutional Administrative Officer

---

Signature of Institutional Administrative Officer                      Date

---

Printed Name of Dean

---

Signature of Dean                                                                      Date

---

Printed Name of Investigator

---

Signature of Investigator                                                              Date

---

Request ID#: 1015644.01

Payee: \_\_\_\_\_  
Institution (Grant payments must be made payable to investigator's degree-granting institution)

Contact Information of Authorized Representative to Receive Payments on behalf of Investigator:

Name: \_\_\_\_\_

Title: \_\_\_\_\_

Address: \_\_\_\_\_

\_\_\_\_\_

City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_

Telephone: \_\_\_\_\_

Fax: \_\_\_\_\_

Email: \_\_\_\_\_